


Guanabenz Acetate

Chemical Properties

CAS No. : 23256-50-0
 Formula: C₈H₈Cl₂N₄·C₂H₄O₂
 Molecular Weight: 291.13
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	Guanabenz Acetate (Wyntensin) is a specific agonist of adrenergic receptor. The pEC ₅₀ for α _{2a} -adrenergic receptor, α _{2b} -adrenergic receptor and α _{2c} -adrenergic receptor is 8.25, 7.01 and ~5, respectively.
Targets(IC ₅₀)	Adrenergic Receptor
In vitro	Guanabenz inhibits the response of vascular contractions in various processes and initiates normal sympathetic nerve discharge, while also antagonizing the stimulation of the sympathetic nervous system. Administering 0.5 mg/kg of Guanabenz intravenously in anesthetized hypertensive rats and dogs leads to a reduction in blood pressure and heart rate. Moreover, an intravenous injection of 0.1 mg/kg Guanabenz in anesthetized dogs initially causes an increase in blood pressure due to the action of the sympathetic nervous system, followed by a decrease in cardiac output, contractility, and heart rate.
In vivo	In mammalian MovS6 cells, 10 μM of Guanabenz facilitates the complete clearance of PrPSc. Additionally, in HEK293 cells transfected with rat inducible nitric oxide synthase (nNOS), 30 μM Guanabenz induces a time-dependent reduction in nNOS activity, with a K _i value of 1 μM. In HEK 293 cells, treatment with 50 μM Guanabenz for 3 hours results in approximately a 75% decrease in the accumulation of nitrites and nitrates within the cells. Furthermore, treatment with 100 μM Guanabenz for 24 hours leads to about a 35% reduction in the quantity of inducible nitric oxide synthase protein detected by immunological methods.

Solubility Information

Solubility	DMSO: 40 mg/mL (137.4 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.87 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.4349 mL	17.1745 mL	34.3489 mL
5 mM	0.687 mL	3.4349 mL	6.8698 mL
10 mM	0.3435 mL	1.7174 mL	3.4349 mL
50 mM	0.0687 mL	0.3435 mL	0.687 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Jasper JR, et al. *Biochem Pharmacol*, 1998, 55(7), 1035-1043.
- Noguchi S, et al. *J Biol Chem*, 2000, 275(4), 2376-2380.
- Tribouillard-Tanvier D, et al. *PLoS One*, 2008, 3(4), e1981.
- Baum T, et al. *J Pharmacol Exp Ther*, 1970, 171(2), 276-287.
- Baum T, et al. *Experientia*, 1969, 25(10), 1066-1067.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481